A Prospective Safety Sub-Registry to Assess Anaphylaxis and Severe Allergic Reactions, and Severe Cutaneous and Systemic Immune-Mediated Reactions with Alglucosidase Alfa Treatment (Pompe Safety Sub-Registry) First published 02/04/2015 Last updated 14/03/2024 EU PAS number:EUPAS9194 Study Finalised